Coulibaly JT, et al. - The effectiveness and safety of escalating praziquantel dosages in preschool-aged children (PSAC) infected with Schistosoma haematobium were evaluated in this study. A randomised, dose-finding trial in PSAC (2–5 years) and as comparator a cohort of school-aged children (SAC) (6–15 years) infected with S. haematobium in Côte d’Ivoire were conducted. According to the findings obtained, praziquantel reported dose-independent efficacy against light infections of S. haematobium. It was noted that praziquantel displayed a ceiling effect with the highest response for 20 mg/kg in PSAC over the dose range tested. Findings revealed that in SAC maximum efficacy was obtained with 40 mg/kg praziquantel.